Literature DB >> 15262304

The development of actinic keratosis into invasive squamous cell carcinoma: evidence and evolving classification schemes.

Jamshaid Anwar1, David A Wrone, Arash Kimyai-Asadi, Murad Alam.   

Abstract

Actinic keratosis is an incipient form of cutaneous squamous cell carcinoma. Consequently, actinic keratoses must be treated expeditiously to forestall their downward growth. Several classification schemes have been proposed to better categorize actinic keratoses, and to guide their diagnosis and treatment. Among these approaches is the "keratinocyte intraepithelial neoplasia" (KIN) system developed by Cockerell; Goldberg's concept of the "proliferative actinic keratosis" (PAK), and Berhane's emphasis on the "inflamed actinic keratosis" (IAK). In the future, disparate classification schemes may be unified into a single pragmatic approach which accurately reflects the biological process whereby actinic keratoses devolve into invasive squamous cell carcinoma.

Entities:  

Mesh:

Year:  2004        PMID: 15262304     DOI: 10.1016/j.clindermatol.2003.12.006

Source DB:  PubMed          Journal:  Clin Dermatol        ISSN: 0738-081X            Impact factor:   3.541


  20 in total

1.  Actinic keratosis treatment as a key component of preventive strategies for nonmelanoma skin cancer.

Authors:  Joel L Cohen
Journal:  J Clin Aesthet Dermatol       Date:  2010-06

2.  The keratin-14 expression in actinic keratosis and squamous cell carcinoma: is this a prognostic factor for tumor progression?

Authors:  Kwang Hyun Choi; Gyong Moon Kim; Si Yong Kim
Journal:  Cancer Res Treat       Date:  2010-06-30       Impact factor: 4.679

3.  Comprehensive review of ultraviolet radiation and the current status on sunscreens.

Authors:  Brummitte Dale Wilson; Summer Moon; Frank Armstrong
Journal:  J Clin Aesthet Dermatol       Date:  2012-09

4.  Tolerability and Pharmacokinetics of Ingenol Mebutate 0.05% Gel Applied to Treatment Areas up to 100cm(2) on the Forearm(s) of Patients with Actinic Keratosis.

Authors:  Lawrence Anderson; Michael Jarratt; George Schmieder; Stephen Shumack; Janelle Katsamas; Peter Welburn
Journal:  J Clin Aesthet Dermatol       Date:  2014-12

5.  Microarray analysis of cutaneous squamous cell carcinomas reveals enhanced expression of epidermal differentiation complex genes.

Authors:  Laurie G Hudson; James M Gale; R Steven Padilla; Gavin Pickett; Bryan E Alexander; Jing Wang; Donna F Kusewitt
Journal:  Mol Carcinog       Date:  2010-07       Impact factor: 4.784

6.  Cost effectiveness of imiquimod 5% cream compared with methyl aminolevulinate-based photodynamic therapy in the treatment of non-hyperkeratotic, non-hypertrophic actinic (solar) keratoses: a decision tree model.

Authors:  Edward C F Wilson
Journal:  Pharmacoeconomics       Date:  2010       Impact factor: 4.981

7.  Influence of Information Framing on Patient Decisions to Treat Actinic Keratosis.

Authors:  Katherine Berry; Melissa Butt; Joslyn S Kirby
Journal:  JAMA Dermatol       Date:  2017-05-01       Impact factor: 10.282

8.  In vivo diagnosis of melanoma and nonmelanoma skin cancer using oblique incidence diffuse reflectance spectrometry.

Authors:  Alejandro Garcia-Uribe; Jun Zou; Madeleine Duvic; Jeong Hee Cho-Vega; Victor G Prieto; Lihong V Wang
Journal:  Cancer Res       Date:  2012-04-05       Impact factor: 12.701

9.  Lip cancer and pre-cancerous lesions harbor TP53 mutations, exhibit allelic loss at 9p, 9q, and 17p, but no BRAFV600E mutations.

Authors:  Gefter Thiago Batista Correa; Vanessa Fátima Bernardes; Silvia Ferreira de Sousa; Marina Gonçalves Diniz; José Maria Porcaro Salles; Renan Pedra Souza; Alfredo Maurício Batista De-Paula; Ricardo Santiago Gomez; Carolina Cavalieri Gomes
Journal:  Tumour Biol       Date:  2015-06-18

10.  Mucin1 expression in focal epidermal dysplasia of actinic keratosis.

Authors:  Enrique Arciniegas; Luz Marina Carrillo; Héctor Rojas; Richard Ramírez; Oscar Reyes; Ambar Suárez; Fabiana Ortega
Journal:  Ann Transl Med       Date:  2015-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.